Detection of aberrant p16 methylation in the serum of colorectal cancer patients

Hongzhi Zou, Baoming Yu, Ren Zhao, Zhiwei Wang, Hui Cang, Donghua Li, Guoguang Feng, Jing Yi

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


OBJECTIVES: To detect aberrant p16 promoter methylation in serum of patients with colorectal cancer (CRC), and to explore the possibility of using this assay in early detection or as a prognostic marker.

METHODS: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and corresponding serum samples. Serum samples from 34 patients with adenomatous polyps and 10 healthy individuals were used as controls. The association of p16 hypermethylation in serum DNA of CRC patients with clinicopathological characteristics was analyzed.

RESULTS: p16 methylation was found in 38% (20 of 52) of CRC tissues. Among the 20 patients with aberrant methylation in the tumor tissues, similar changes were also detected in the serum of 14 (70%) patients. No methylated p16 sequences were detected in the peripheral serum of the 32 CRC patients without these changes in the tumor, in 34 paitents with adenomatous polyps, or in 10 healthy controls. Clinicopathological analysis revealed that p16 methylation in serum was significantly associated with later Dukes' stage (chi(2) = 5.7, P = 0.03).

CONCLUSION: This assay offers a potential means for the serum-based detection and/or monitoring of CRC patients.

Original languageEnglish (US)
Pages (from-to)499-501
Number of pages3
JournalZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Issue number7
StatePublished - Dec 1 2002

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Detection of aberrant p16 methylation in the serum of colorectal cancer patients'. Together they form a unique fingerprint.

Cite this